Cipla Doxorubicin 10mg. 50mg Injection
PDF Leaflet Revision Date: 27 July 2012
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including leukaemias and solid tumors.
Dosage (summary)
60-90 mg/m2 every 3-4 weeks; adjust for hepatic impairment.
Special Populations
- Elderly
- Hepatic impairment
- Obese patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Additive toxicity with other cytotoxic agents
- Cardiotoxic drugs
Contraindications
- Hypersensitivity to doxorubicin
- Persistent myelosuppression
- Hepatic impairment
- Myocardial insufficiency
- Recent myocardial infarction
Common side effects
- Leukopenia
- Nausea
- Vomiting
- Alopecia
- Cardiac abnormalities
Counselling Points
- Avoid pregnancy
- Use effective contraception
- Monitor for signs of infection
Serious warnings
- Cardiotoxicity risk
- Monitor cardiac function
- Incompatible with heparin
Important Disclaimer
The Cipla Doxorubicin 10mg. 50mg Injection professional information leaflet below is the property of Cipla and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
